September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical spironolactone in the treatment of meibomian gland dysfunction
Author Affiliations & Notes
  • Richard W Yee
    Ophthalmology , Richard W Yee MD PLLC , Houston, Texas, United States
  • Brian Wong
    Ophthalmology , Richard W Yee MD PLLC , Houston, Texas, United States
  • Mikhail Lagrimas de Jesus
    Ophthalmology , Richard W Yee MD PLLC , Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Richard Yee, Richard W Yee MD PLLC (P); Brian Wong, None; Mikhail de Jesus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5664. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Richard W Yee, Brian Wong, Mikhail Lagrimas de Jesus; Topical spironolactone in the treatment of meibomian gland dysfunction. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5664.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The objective of this study was to investigate the effectiveness of topical spironolactone in treating MGD, a major component of dry eye syndrome.

Methods : Twenty patients with moderate to severe meibomian gland disease were included in this study. Patients who were taking glaucoma medications, steroid eye drops and other lipid-altering eye drops were excluded from the study. Subjective global dry eye assessment, keratitis and conjunctival staining, anterior blepharitis grade, gland obstruction grade, meibum turbidity grade, meibum viscosity grade, zone A posterior lid margin grade, best corrected vision, and Schirmer‘s score were compared in a pre-post study. Follow-up times ranged from 1 to 7 weeks, with an average of approximately 3 weeks. Statistical analysis was performed using STATA 13 by fitting scored data to a non-parametric model

Results : Patients with moderate to severe MGD had improved self-reported global assessment scores (p = 0.010), turbidity score (p = 0.001), and Zone A scores (p = 0.025) after treatment with topical ophthalmic suspensions of spironolactone.

Conclusions : MGD patients reported improved dry eye symptoms after a week of using spironolactone suspension. The quality of expressed meibum secretions of patients showed improved clarity and viscosity post-treatment. Inflammation decreased at the avascular region posterior to the posterior lid margin post-treatment.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.